Screener
Pacira BioSciences, Inc. PCRX Operating Income
Operating Income at other companies
Other financials
Where this comes from
Reported directly by Pacira BioSciences, Inc. in its filing.
Tagged under the XBRL concept us-gaap:OperatingIncomeLoss.
The source filing: Pacira BioSciences, Inc.’s 10-Q, filed April 30, 2026.
- Filed
- Apr 30, 2026, 4:07 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001628280-26-028871
| Line item | Three Months Ended March 31, 2026 | 2025 |
|---|---|---|
| Amortization of acquired intangible assets | 14,322 | 14,322 |
| Other operating (gains) expenses, net | (2,277) | 6,187 |
| Total operating expenses | 170,474 | 166,933 |
| Income from operations | 6,902 | 1,990 |
| Other income (expense): | ||
| Interest income | 1,930 | 6,895 |
| Interest expense | (3,699) | (4,580) |
| Other, net | (135) | 4,401 |
Item 1. FINANCIAL STATEMENTS (Unaudited)
FAQ
- What is Pacira BioSciences, Inc.'s operating income?
- Pacira BioSciences, Inc. (PCRX) reported operating income of $6.9M in Q1 2026.
- How has Pacira BioSciences, Inc.'s operating income changed year-over-year?
- Pacira BioSciences, Inc.'s operating income increased by 246.8% year-over-year, from $1.99M to $6.9M.
- What is the long-term trend for Pacira BioSciences, Inc.'s operating income?
- Over 2 years (2021 to 2025), Pacira BioSciences, Inc.'s operating income has grown at a -53.8% compound annual growth rate (CAGR), from $89.92M to $19.19M.
- What does operating income mean?
- Gross profit minus all operating expenses (SG&A, R&D, D&A). Measures the profit from core business operations before interest, taxes, and non-operating items.
Ask your AI about Pacira BioSciences, Inc.'s operating income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude